How have APS shares performed in 2024?

Aptose Biosciences' stock was trading at C$3.35 on January 1st, 2024. Since then, APS stock has decreased by 47.8% and is now trading at C$1.75. View the best growth stocks for 2024 here .

When is Aptose Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our APS earnings forecast .

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (TSE:APS) posted its quarterly earnings data on Tuesday, March, 26th. The biotechnology company reported ($1.96) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.98) by $0.02.

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aptose Biosciences (APTO) , Aurinia Pharmaceuticals (AUPH) , Advanced Micro Devices (AMD) , NVIDIA (NVDA) , Aurora Cannabis (ACB) , Adobe (ADBE) , AltaGas (ALA) , Aphria (APHA) , Algonquin Power & Utilities (AQN) and Badger Daylighting (BAD) .

How do I buy shares of Aptose Biosciences?

Shares of APS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

TSE:APS

Aptose Biosciences (APS) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free APS Stock Alerts

C$1.75

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: C$1.74
▼
C$1.85
50-Day Range: C$1.75
▼
C$2.78
52-Week Range: C$1.71
▼
C$11.40

Volume: 10,978 shs
Average Volume: 8,872 shs
Market Capitalization: C$27.49 million

P/E Ratio: N/A
Dividend Yield: 0.39%
Price Target: N/A

Stock Analysis Chart Competitors Earnings Headlines Insider Trades

Get Aptose Biosciences alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Aptose Biosciences Stock (TSE:APS)

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

APS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

APS Stock News Headlines

March 28, 2024 | seekingalpha.com

Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript

March 25, 2024 | benzinga.com

Aptose Biosciences's Earnings: A Preview

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

January 31, 2024 | finance.yahoo.com

Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option

December 20, 2023 | theglobeandmail.com

Closing Bell: Aptose Biosciences Inc flat on Wednesday (APS)

December 9, 2023 | finance.yahoo.com

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

November 30, 2023 | finance.yahoo.com

Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

November 10, 2023 | finance.yahoo.com

Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call Transcript

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

November 9, 2023 | finance.yahoo.com

Aptose Reports Results for the Third Quarter 2023

November 2, 2023 | theglobeandmail.com

Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting

November 2, 2023 | finance.yahoo.com

Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting

October 30, 2023 | finanznachrichten.de

Aptose Biosciences, Inc.: Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

October 26, 2023 | finance.yahoo.com

Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023

October 20, 2023 | markets.businessinsider.com

Promising Prospects of Tuspetinib Drive Buy Rating for Aptose Biosciences: An Analyst’s Perspective

October 7, 2023 | theglobeandmail.com

Closing Bell: Aptose Biosciences Inc up on Friday (APS)

August 25, 2023 | theglobeandmail.com

Closing Bell: Aptose Biosciences Inc up on Thursday (APS)

August 22, 2023 | theglobeandmail.com

Closing Bell: Aptose Biosciences Inc flat on Monday (APS)

August 11, 2023 | finanznachrichten.de

Aptose Biosciences, Inc.: Aptose Reports Results for the Second Quarter 2023

August 11, 2023 | finance.yahoo.com

Aptose Reports Results for the Second Quarter 2023

August 7, 2023 | theglobeandmail.com

Aptose Biosciences: Top 10 Undervalued Biotechnology Industry Stocks (APS)

July 21, 2023 | theglobeandmail.com

Aptose Biosciences: Stocks Undervalued by Analyst Consensus on TSX (APS)

June 27, 2023 | finanznachrichten.de

Aptose Biosciences, Inc.: Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

June 5, 2023 | finanznachrichten.de

Aptose Biosciences, Inc.: Aptose Biosciences Provides Update on Reverse Stock Split

May 31, 2023 | finance.yahoo.com

Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023

May 26, 2023 | seekingalpha.com

Aptose to sell up to $25M stock in the U.S.

May 17, 2023 | theglobeandmail.com

Closing Bell: Aptose Biosciences Inc flat on Tuesday (APS)

See More Headlines

Receive APS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/26/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/13/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: TSE:APS
CUSIP: N/A
CIK: N/A
Web: aptose.com
Phone: +1-647-4799828
Fax: N/A
Employees: 31
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): C($10.49)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: C$-51,210,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -225.00%
Return on Assets: -102.23%

Debt

Debt-to-Equity Ratio: 14.27
Current Ratio: 0.78
Quick Ratio: 5.41

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: C$1.09 per share
Price / Cash Flow: 1.60
Book Value: C$1.03 per share
Price / Book: 1.70

Miscellaneous

Outstanding Shares: 15,710,000
Free Float: N/A
Market Cap: C$27.49 million
Optionable: Not Optionable
Beta: 1.44

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Dr. William G. Rice Ph.D. (Age 59)
Chairman, Pres & CEO
Mr. Gregory K. Chow CPA (Age 45)
MBA, BA, Sr. VP, CFO & Principal Accounting Officer
Mr. Ernest Kitt B.S.
M.S, VP of Devel. & Technical Operations
Dr. Stephen B. Howell (Age 73)
Chief Medical Officer
Mr. Peter Murray
Director of Clinical Devel.

Key Competitors

View All Competitors

APS Stock Analysis - Frequently Asked Questions

How have APS shares performed in 2024?: Aptose Biosciences' stock was trading at C$3.35 on January 1st, 2024. Since then, APS stock has decreased by 47.8% and is now trading at C$1.75.
View the best growth stocks for 2024 here.
When is Aptose Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our APS earnings forecast.
How were Aptose Biosciences' earnings last quarter?: Aptose Biosciences Inc. (TSE:APS) posted its quarterly earnings data on Tuesday, March, 26th. The biotechnology company reported ($1.96) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.98) by $0.02.

What other stocks do shareholders of Aptose Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), Advanced Micro Devices (AMD), NVIDIA (NVDA), Aurora Cannabis (ACB), Adobe (ADBE), AltaGas (ALA), Aphria (APHA), Algonquin Power & Utilities (AQN) and Badger Daylighting (BAD).
How do I buy shares of Aptose Biosciences?: Shares of APS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:APS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aptose Biosciences (APS) Stock Price, News & Analysis

About Aptose Biosciences Stock (TSE:APS)

APS Stock Price History

APS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

APS Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info